Brand & Product Security

Articles

What 2025 means for the life sciences sector in the New Year.

Pharma's Year of Two Halves 

. He can be reached at nsaraceno@mjhlifesciences.com.

Podcasts

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.

Pharma Pulse: PBM Reform Hits the Courtroom and Telehealth’s Legislative Victory

Policy shifts bring meaningful improvements for some—but looming coverage losses and rising premiums threaten to erase those gains.

What Does Healthcare Look Like for Patients in 2026?

In today’s Pharma Pulse, AstraZeneca faces a complete response letter for its self-injectable lupus drug, while the EMA gives the green light to a historic wave of new therapies for MASH, rare diseases, and postmenopause.

Pharma Pulse: AstraZeneca’s US Setback and Europe’s Medicine Marathon

The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.

Morris & Dickson Acquires Prodigy Health to Expand Specialty and Plasma Distribution Capabilities

Associate Editorial Director
Pharmaceutical Commerce

Even the threat of Greenland-related tariffs rattled drug supply chains and uncovered industry vulnerabilities to instability. 

Pharma Industry Uncertainty in Wake of On/Off Greenland Tariffs

In today’s Pharma Pulse, the United States finalizes its departure from global health oversight, while domestic providers face a record-breaking surge in respiratory hospitalizations.

Pharma Pulse: US Exits the World Health Organization; Hospitals Overwhelmed by Historic Flu Crisis

The agency will evaluate FISP after early results show major gains in speed, capacity, and real-time risk mitigation across US ports of entry.

FDA Reviews ImportShield Program as Processing Gains Boost Import Oversight and Supply Chain Protection

Videos

Artificial intelligence is helping pharma teams uncover critical safety signals faster, lower costs, and shift pharmacovigilance from compliance to competitive advantage.

The Future of Drug Safety

In today’s Pharma Pulse, Congress races to secure funding, while Novavax nets a half-billion-dollar validation of its non-aluminum vaccine technology.

Legal & Regulatory